You are here
Ferring Pharmaceuticals Donates $1M to Alliance for Fertility Preservation
Ferring Pharmaceuticals Inc. has announced that it will donate $1 million to the Alliance for Fertility Preservation (the Alliance), a non-profit organization that aims to promote a dialogue between cancer patients and clinicians to help them make informed decisions about fertility preservation and manage infertility following cancer treatment.
Each year over 70,000 women in their 20s and 30s are diagnosed with cancer, and less than half of cancer survivors of childbearing age recall having a discussion about future fertility or the effects of their treatment on fertility.
“As cancer survival rates increase, more and more patients need to consider their life after treatment, including how they might build or expand their family,” said Joy Lewin, Director of Ferring’s reproductive health unit. “Unfortunately, when faced with the overwhelming decisions surrounding their cancer diagnosis, future fertility is not top of mind. We believe it’s imperative to drive a better dialogue between healthcare providers and patients, which is why Ferring is supporting the Alliance in meeting this unmet need.”
“Building on the American Society of Clinical Oncology’s guidelines, the Alliance will work to identify different ways to assist physicians within different communities to help them educate their patients about fertility preservation and to provide support which enables patients to make informed decisions about their fertility options,” said John Mulhall, M.D., Chairman of the Alliance for Fertility Preservation and urologist at Memorial Sloan Kettering Cancer Center. Ferring’s donation will help develop and support these initiatives.